Matthew P. Goetz, MD of Mayo Clinic @MayoClinic discusses acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib…
Browsing: Other
Lipika Goyal, MD of Massachusetts General Hospital @MassGeneralNews discusses the data for futibatinib in advanced intrahepatic cholangiocarcinoma. Read here:Â https://www.prnewswire.com/news-releases/taiho-oncology-announces-presentation-of-data-for-futibatinib-in-advanced-intrahepatic-cholangiocarcinoma-at-2020-asco-meeting-301068213.html?tc=eml_cleartime
Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted…
Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted…
Matthew S. Davids, MD of Dana Farber Cancer Institute @DanaFarber discusses a multicenter phase II study of venetoclax plus dose-adjusted…
Alex Spira, MD, PhD of Virginia Cancer Specialists @VCSpecialists discusses PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term…
Alex Spira, MD, PhD of Virginia Cancer Specialists @VCSpecialists discusses CX-2029, a PROBODY drug conjugate targeting CD71: Results from a…
Michael Lim, MD of The Johns Hopkins Hospital @hopkinskimmel discusses the phase I trial of anti-LAG-3 alone and in combination…
Michael Lim, MD of The Johns Hopkins Hospital @hopkinskimmel discusses the phase I trial of anti-LAG-3 alone and in combination…
Michael Lim, MD of The Johns Hopkins Hospital @hopkinskimmel discusses the phase I trial of anti-LAG-3 alone and in combination…
Debra Patt, MD, PhD of Texas Oncology discusses driving quality improvement: how clinical decision support can facilitate compliance with evidence-based…
Debra Patt, MD, PhD of Texas Oncology discusses driving quality improvement: how clinical decision support can facilitate compliance with evidence-based…
Debra Patt, MD, PhD of Texas Oncology discusses driving quality improvement: how clinical decision support can facilitate compliance with evidence-based…
Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses phase I/II clinical trial of autologous CMV-specific cytotoxic t-cells…
Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses phase I/II clinical trial of autologous CMV-specific cytotoxic t-cells…
Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses the safety and clinical efficacy of atezolizumab (atezo; aPDL1)…
Shiao-Pei S. Weathers, MD of MD Anderson Cancer Center @MDAndersonNews discusses the safety and clinical efficacy of atezolizumab (atezo; aPDL1)…
Laurence Cooper, MD, PhD on controlled, survival of subjects, and final results in IL-12 in combination with a PD-1 inhibitor…
Jeffrey Weitzel, MD of City of Hope @cityofhope discusses clinical conundrums: developing a strategy for discerning TP53-associated chip and coherent…
Jeffrey Weitzel, MD of City of Hope @cityofhope discusses clinical conundrums: developing a strategy for discerning TP53-associated chip and coherent…
Jeffrey Weitzel, MD of City of Hope @cityofhope discusses clinical conundrums: developing a strategy for discerning TP53-associated chip and coherent…
Chung-Han Lee, MD @ChungHanLee3 of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses the KEYNOTE-146/Study 111: Phase II trial of lenvatinib…
Chung-Han Lee, MD @ChungHanLee3 of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses the KEYNOTE-146/Study 111: Phase II trial of lenvatinib…
Chung-Han Lee, MD @ChungHanLee3 of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses the KEYNOTE-146/Study 111: Phase II trial of lenvatinib…
Scott Tomlins, MD, PhD of Strata Oncology @StrataOncology discusses PCR-based comprehensive genomic profiling (PCR-CGP): feasibility from >20,000 tissue specimens and…
Scott Tomlins, MD, PhD of Strata Oncology @StrataOncology discusses PCR-based comprehensive genomic profiling (PCR-CGP): feasibility from >20,000 tissue specimens and…
Scott Tomlins, MD, PhD of Strata Oncology @StrataOncology discusses PCR-based comprehensive genomic profiling (PCR-CGP): feasibility from >20,000 tissue specimens and…
Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study…
Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study…
Jorge Cortes, MD of Georgia Cancer Center at Augusta University discusses the interim analysis (IA) of OPTIC: a dose-ranging study…
Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced…
Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced…
Danny Rischin, MD of Peter MacCallum Cancer Centre @PeterMacCC discusses the phase II study of cemiplimab in patients with advanced…
Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667)…
Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667)…
Vivek Subbiah, MD @VivekSubbiah of MD Anderson Cancer Center @MDAndersonNews discusses the clinical activity of the RET inhibitor pralsetinib (BLU-667)…
Krystal Cascetta, MD of Icahn School of Medicine at Mount Sinai @IcahnMountSinai discusses oncotype recurrence scores in invasive lobular carcinomas.
Krystal Cascetta, MD of Icahn School of Medicine at Mount Sinai @IcahnMountSinai discusses oncotype recurrence scores in invasive lobular carcinomas.
Andrew Krivoshik, MD of Astellas @AstellasUS discusses what is net for Astellas.
David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently…
David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently…
David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently…
Amar Gajjar, MD of St. Jude Children’s Research Hospital @StJudeResearch discusses genomics paving the way to better infant medulloblastoma therapy…
Amar Gajjar, MD of St. Jude Children’s Research Hospital @StJudeResearch discusses genomics paving the way to better infant medulloblastoma therapy…
Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results.…
Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results.…
Henry Gómez of Oncosalud – AUNA discusses real-world evidence shows for the first time the practice-changing impact of TAILORx results.…
Kent Nastiuk, MD of Roswell Park @RoswellPark discusses prostate tumor-derived GDF11 accelerates androgen deprivation therapy–induced sarcopenia. Read here: https://insight.jci.org/articles/view/127018?utm_source=Cision&utm_medium=Email&utm_term=Apr-20%60&utm_content=cancer%2c+melanoma%2c+prostate%2c+pancreatic%2c+rectal%2c+treatment%2c+studies%2c+research
Kent Nastiuk, MD of Roswell Park @RoswellPark discusses prostate tumor-derived GDF11 accelerates androgen deprivation therapy–induced sarcopenia. Read here: https://insight.jci.org/articles/view/127018?utm_source=Cision&utm_medium=Email&utm_term=Apr-20%60&utm_content=cancer%2c+melanoma%2c+prostate%2c+pancreatic%2c+rectal%2c+treatment%2c+studies%2c+research
Nicholas Vogelzang, MD of Comprehensive Cancer Center @CCCNevada discusses the single arm, phase 2, TRITON2 clinical trial supported FDA approval…